Vicarious Surgical (RBOT) Liabilities and Shareholders Equity (2020 - 2025)
Vicarious Surgical (RBOT) posted quarterly Liabilities and Shareholders Equity of $19.6 million for Q4 2025, down 71.08% year-over-year from $67.7 million in Q4 2024, and down 33.28% quarter-over-quarter from $29.3 million in Q3 2025.
Vicarious Surgical (RBOT) Liabilities and Shareholders Equity (2020 - 2025) Analysis & Trends
Vicarious Surgical (RBOT) has reported Liabilities and Shareholders Equity for 6 consecutive years, with $19.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Liabilities and Shareholders Equity fell 71.08% year-over-year to $19.6 million; the TTM figure through Dec 2025 stood at $144.9 million (down 58.25% YoY), while the FY2025 annual figure was $19.6 million, down 71.08% from the prior year.
- Liabilities and Shareholders Equity eased to $19.6 million in Q4 2025 per RBOT's latest filing, from $29.3 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $346.4 million in Q1 2021 and bottomed at $19.6 million in Q4 2025.
- Historically, Liabilities and Shareholders Equity has averaged $133.6 million across 5 years, with a median of $120.5 million in 2023.
- Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity jumped 89224.63% — and 2025, when it sank 71.08%.
- Vicarious Surgical's Liabilities and Shareholders Equity stood at $181.7 million in 2021, then retreated by 22.78% to $140.3 million in 2022, then declined by 14.56% to $119.9 million in 2023, then plunged by 43.5% to $67.7 million in 2024, then slumped by 71.08% to $19.6 million in 2025.
- Business Quant data shows RBOT's Liabilities and Shareholders Equity at $19.6 million in Q4 2025, $29.3 million in Q3 2025, and $40.9 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.95 Bn | 193.35 Bn | 7.27 Bn | 109.22 Bn |
| 2 | Stryker | 128.10 Bn | 124.63 Bn | 4.50 Bn | 47.93 Bn |
| 3 | Medtronic | 118.91 Bn | 109.69 Bn | 6.41 Bn | 93.03 Bn |
| 4 | Boston Scientific | 73.43 Bn | 72.89 Bn | 3.85 Bn | 45.22 Bn |
| 5 | Edwards Lifesciences | 51.91 Bn | 47.66 Bn | 1.35 Bn | 13.87 Bn |
| 6 | Dexcom | 34.52 Bn | 32.58 Bn | 830.00 Mn | 6.46 Bn |
| 7 | GE HealthCare Technologies | 33.94 Bn | 31.83 Bn | 2.18 Bn | 37.25 Bn |
| 8 | Koninklijke Philips | 26.37 Bn | 23.05 Bn | 4.55 Bn | 31.04 Bn |
| 9 | Steris | 23.14 Bn | 22.66 Bn | 684.20 Mn | 10.74 Bn |
| 10 | Vicarious Surgical | 196,495.36 | -14.84 Mn | - | 19.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 19.58 Mn |
| Sep 30, 2025 | 29.35 Mn |
| Jun 30, 2025 | 40.89 Mn |
| Mar 31, 2025 | 55.05 Mn |
| Dec 31, 2024 | 67.72 Mn |
| Sep 30, 2024 | 80.62 Mn |
| Jun 30, 2024 | 93.35 Mn |
| Mar 31, 2024 | 105.29 Mn |
| Dec 31, 2023 | 119.86 Mn |
| Sep 30, 2023 | 132.05 Mn |
| Jun 30, 2023 | 104.53 Mn |
| Mar 31, 2023 | 121.09 Mn |
| Dec 31, 2022 | 140.29 Mn |
| Sep 30, 2022 | 150.68 Mn |
| Jun 30, 2022 | 164.05 Mn |
| Mar 31, 2022 | 179.97 Mn |
| Dec 31, 2021 | 181.68 Mn |
| Sep 30, 2021 | 193.36 Mn |
| Jun 30, 2021 | 345.54 Mn |
| Mar 31, 2021 | 346.35 Mn |